Nowadays, it is largely accepted that DAMPs will initiate sterile immune-inflammation responses by inducing the activation of multiple classic pattern recognition receptors (PRRs), including membrane-bound TLRs and CLRs, cytoplasmic NLRs, and multiple intracellular DNA or RNA sensors, such as TLR3/7/9, cyclic GMP-AMP synthase, absent in melanoma 2, retinoic acid inducible gene I–like receptors, and melanoma differentiation-associated protein 5 (MDA5) (9, 45, 46). The gene discussed is LARS1; the disease is melanoma.